Please provide your email address to receive an email when new articles are posted on . LAS VEGAS – “Digital eye exams are a huge opportunity for the industry,” Aaron Dallek, CEO and co-founder of ...
Refractory dry eye in patients with systemic comorbidities can be challenging to manage because the underlying condition or ...
Please provide your email address to receive an email when new articles are posted on . SEATTLE – Refracting patients with a device that uses point spread function instead of Snellen letters provides ...
Incyte Announces European Commission Approval of Minjuvi® (tafasitamab) for the Treatment of Relapsed or Refractory Follicular Lymphoma ...
In a phase 1 trial, axicabtagene ciloleucel (axi-cel), an autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy, showed efficacy in patients with refractory large B-cell lymphoma after ...
ASH 2025 oral presentation on SENTI-202 in 20 Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) patients (18 response evaluable) shows high efficacy: 50% ORR and 42% CR/CRh (100% of CRs and 83% of ...
Secondary Neoplasms After Hematopoietic Cell Transplant for Sickle Cell Disease As of January 31, 2022, 157 patients were treated (median age, 64 years [range, 20‐83]; median of three [range, 2-11] ...
Incyte Japan Announces Approval of Minjuvi® (tafasitamab) in Combination with Rituximab and Lenalidomide for Relapsed/Refractory Follicular Lymphoma ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback